ABSTRACT
INTRODUCTION Late-life onset psychosis is associated with faster progression to dementia in cognitively normal people, but little is known about its relationship to cognitive impairment in advance of dementia.
METHODS Clinical and genetic data from 2,750 people over 50 without dementia were analyzed. Incident cognitive impairment was operationalized using the IQCODE and psychosis (MBI-psychosis) was rated using the Mild Behavioral Impairment Checklist. The whole sample was analyzed before stratification on APOE-ε4 status.
RESULTS In Cox proportional hazards models, MBI-psychosis had a higher hazard rate (HR) for cognitive impairment relative to the No Psychosis group (HR:3.6, 95% CI:2.2-6, p<0.0001). The HR for MBI-psychosis was higher in APOE-ε4 carriers and there was an interaction between the two (HR for interaction: 3.4, 95% CI:1.2-9.8, p=0.02).
DISCUSSION Psychosis assessment in the MBI framework is associated with incident cognitive impairment in advance of dementia, these symptoms may be particularly important in the context of APOE genotype.
Competing Interest Statement
Clive Ballard has received contract grant funding from ACADIA, Lundbeck, Takeda, and Axovant pharmaceutical companies and honoraria from Lundbeck, Lilly, Otsuka, and Orion pharmaceutical companies. Dag Aarsland has received research support and/or honoraria from Astra-Zeneca, H. Lundbeck, Novartis Pharmaceuticals, and GE Health, and serves as a paid consultant for H. Lundbeck and Axovant. Zahinoor Ismail has received honoraria/consulting fees from Janssen, Lundbeck, and Otsuka, although not related to this work.
Funding Statement
This work was funded in part through the MRC Proximity to Discovery: Industry Engagement Fund (External Collaboration, Innovation and Entrepreneurism: Translational Medicine in Exeter 2 (EXCITEME2) ref. MC_PC_17189) awarded to Dr Creese. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and Kings College London. None of the funding bodies had any role in the design, analysis or interpretation of data, or the drafting of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
London Bridge NHS Research Ethics Committee has approved this research (Ref: 13/LO/1578)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available via request to the PROTECT study.
